ASCO 2024

Immunotherapy makes a difference in survival in eTNBC

The search for predicitve biomarkers continues

Prognostic value of ctDNA in therapeutic strategies; Endocrine therapy in ER-low BC

Avelumab in early TNBC

AI for the prediction of disease progression

Adjuvant endocrine therapy for ER-low EBC

Personalized neoadjuvant therapy for high-risk breast cancer patients

Advantage for node-negative patients

ctDNA important for HR+ eBC?

ctDNA analysis in monarchE

Ribociclib is also effective in N0 HR+/HER2− EBC

Avelumab nel TNBC precoce

One step closer to chemo-free therapy for HR+/HER2+ patients

Expanding T-DxD use to HER2 ultra-low - the success story continues

Reassuring and clarifying new data for CDK4/6 inhibitors

Improvement for firstline treatment for patients with endocrine resistance

ER-low: endocrine therapy necessary after all?

New data on the omission of chemotherapy in young patients

Responder premenopausal

Systemic therapy of HER2+ patients with brain metastases

Leptomeningeal metastases in HER2+ mBC

Eribulin, Trastuzumab, Pertuzumab in 1stL HER2+ mBC

Heterogenity of ER+ disease

Triple positive mBC - chemotherapy unnecessary?

Is there still a place for endocrine therapy in HER2+ BC

Novel ADC-ICI combination therapy

Broaden T-DXD as therapy standard for HER2low and ultra-low MBC

Important OS benefit with T-Dxd in HER2+ mBC

HER2+ mBC 1stL T-Dxd

The ADC revolution continues - ctDNA takes the next step in tumor characterization

Decreasing SG related toxicity with profilatic G-CFS

Sacituzumab tirumotecan - a new powerful ADC for advanced TNBC

T-DXD continues its impressive track record for MBC patients

Expanding use of T-DxD in HER2low and HER2 ultra-low MBC patients

Ultra low - ultra good?

Already more in the 1stL?

Chemo-free regimen in HER2+ luminal breast cancer

Endocrine therapy with Palbociclib + Trastuzumab

INAVO120 - updated results

CDK4/6 rechallenge

Chemo-free, CDK4/6 inhibitor-based combination active in HR+/HER2+ PAM50-luminal advanced breast cancer

Treatment beyond progression for CDK 4/6i

CDK4/6i effective in premenopausal patients as well

First-line inavolisib/placebo + palbociclib + fulvestrant preferred in patients with PIK3CA HR+ HER2- advanced breast cancer

Sacituzumab tirumotecan – nowy aktywny koniugat w leczeniu zaawansowanego raka trójujemnego

La révolution de l'ADC se poursuit / ctDNA franchit une nouvelle étape dans la caractérisation des tumeurs

CDK4/6 rechallenge

Le traitement endocrinien a-t-il encore sa place dans la CB HER2+ ?

Regime senza chemioterapia nel carcinoma mammario luminoso HER2+

Disminución de la toxicidad relacionada con la OS con G-CSF y loperamide profiláctica

C'è ancora posto per la terapia endocrina nel BC HER2+?

Espansione dell'uso di T-DxD nelle pazienti con carcinoma mammario metastatico HER2-low e HER2 ultra-low

INAVO120: risultati aggiornati

Leczenie bez chemioterapii, oparte na inhibitorze CDK4/6 aktywne w zaawansowanych rakach HR+/HER2+ o fenotypie luminalnym wg PAM50

Importante beneficio en la supervivencia global con TDxD en el CMm HER2+

Interesting data - but not practice changing

Is the metformin story over? How to treat HFNS symptomatology?

Focus on Quality of Life

PSMA-PET CT: Ready for clinical practice or a PROMISE for the future?

Exploring the CHAARTED TRIAL: Optimizing Treatment Strategies in Metastatic Prostate Cancer

RCT in mCRPC

Unveiling the Potential: PSMA-PET in Prostate Cancer Staging - Insights from the PROMISE TRIAL

The evolving role of PSMA-PET with new agents

ARASENS Post hoc analysis: Therapy after progression

EMBARK: Quality of Life

Radionukleotides - the next step forward

Unlocking Insights: The ALLIANCE Trial redefining Prognostic Models in Metastatic Prostate Cancer

Deciphering EMBARK: Exploring Enzalutamide's Impact on Prostate Cancer Progression and Quality of Life

Important QoL data

mCRCP CYCLONE 2 study

mCRPC: Who benefits from which measures?

EMBARK demonstrates the importance of HRQoL benefit in both combination and monotherapy arms

Perioperative treamtent in MIBC - new data for the use of sacituzumab govitecan

EV-Pembro shows consistent outcome - caution with subset analyses

Treatment of urachal carcinoma

ctDNA as a biomarker in metastatic bladder cancer

Preoperative use of sacituzumab govitecan

Modified FOLFIRINOX therapy as a good option for urachus carcinoma

Biomarkers and long-term outcomes in pts with low tumor burden

Effect of an immune diet on the outcome after radical cystectomy

ASCO 2024: Time for the rare GU tumors?

Quality of life not affected by i. v. Pembro

MI-UC - News from EVP standard

What to do with Cis Gem Nivo?

The Role of Topoisomerase Inhibitors in the preoperative setting of MIBC: The story has just begun

The future of sacituzumab govitecan

Interim analysis of the SURE-01/02 study

ASCO24: Bladder cancer highlights

ASCO 2024: momento para los tumores GU poco frequentes?

ASCO24: Bladder cancer highlights

El papel de los inhibidores de topoisomerasa en el contexto perioperatorio del cancer de vejiga musculo infiltrante: la historia acaba de empezar

El futuro de sacituzumab govitecan

Biomarcadores y resultados a largo plazo en pacientes con baja carga tumoral

Supportive real-world data from German research platform CARAT

Evaluating risk criteria and monotherapy in mRCC

Advancing our understanding of biological mechanisms and the quest for the Ideal biomarker - Part 1

Advancing Our Understanding of Biological Mechanisms and the Quest for the Ideal Biomarker - Part 2

Combination is superior to monotherapy - how do we translate the results into clinical practice?

NIVO+CABO: significantly longer therapy-free time

The never ending saga of biomarkers

Combination therapies for chromophobe renal cell carcinoma are clearly superior

Biomarker analysis of KN426 & CLEAR

Adjuvant KIM-1 as prognostic & predictive biomarker

KIM-1: Will have a major impact

DFF332 a novel HIF inhibitor

nccRCC

Belzutifan in earlier lines in advanced ccRCC

The search of the ideal biomarker in advanced renal cell carcinoma: The Sisyphus myth?

Another breakthrough perioperative

Treatment of favorable prognosis mRCC patients: additional data to support treatment decisions

Metastasized chromophobe RCC

New HIF inhibitor in clear cell RCC

KIM-1 - old wine in new bottles

New IMDC risk group - very favorable

La busqueda del marcador ideal en el cancer renal avanzado: el mito de Sísifo?

Tratamiento del cancer renal avanzado de pronostico favorable: datos adicionales para ayudar en la decision clinica

Adjuvant therapy: how to identify patients who will benefit

End of the story in EGFRm disease?

Osimertinib improves PFS in stage III

4y follow-up of CheckMate 816

Early change in SOC in EGFR+ LD-NSCLC

ctDNA predicts outcome in patients treated with osimertinib

Perioperative chemotherapy and N2 status

CheckMate 816: 4-year update

4-year efficacy of Keynote-799 and ctDNA

Gamechanger in EGFR-mutated NSCLC

Liquid biopsy in curative situation

Confirmed efficacy of periop IO in N2 R-NSCLC

Stadium III EGFR+: now permanently Osimertinib?!

4y follow-up de CheckMate 816

Cambio temprano en el tratamiento estándar del EGFR+ LD-NSCLC

Le traitement adjuvant par osimertinib apres CTRT : changement de donne dans le cas du CBNPC muté EGFR

Lorlatinib with extraordinary data in ALK + NSCLC

Update for EGFR-positive NSCLC

TROP2-targeting ADCs: where a we heading?

KRAS in NSCLC - a lot to come

The end for local therapy for oligometastatic disease

BAY2927088 - Promising Her2-Inhibitor in NSCLC

ASCO 2024 highlights

KRASG12C - the story continues

KRAS building on single agent therapy

Lorlatinib convincing in ALK mutation 1st line

Adagrasib for KRASG12C mutation 2nd line

Subcut amivantamab - the future

Telehealth is just as effective as a face-to-face visit in early palliative care

Confirmed efficacy of adagrasib in KRASG12C

EGFR+ NSCLC - amivantamab-based combination therapy

Confirmed efficacy in PD-L1 negativity - CheckMate 9LA

ADCs - moving landscapes. Subgroups remain to be defined.

ALK+ NSCLC - CROWN revisited

La télésanté est aussi efficace qu'une consultation face a face dans les soins palliatifs précoces

KRASG12C - het verhaal gaat verder

Het einde van lokale therapie voor oligometastatische ziekte

BAY297088 - Inhibiteur Her2-Inhibitor dans le NSCLC

ASCO 2024 highlights

ASCO 2024 highlights

Redefining SOC in LD-SCLC: Durvalumab as consolidation therapy

New SoC for LD-SCLC

Tarlatamab shows activity in patients with brain metastasis

LD-SCLC: What´s about PCI?

Maintenance with durvalumab is the new SOC after chemo/radio therapy for LD-SCLC

Finally, change for LS-SCLC

Tot slot, verandering voor LS-SCLC

Le traitement d'entretien avec le durvalumab est le nouveau SOC après la chimio/radiothérapie pour le carcinomes à petites cellules en forme limitée

Unexpected results; which subgroup could benefit from atezolizumab?

Harsh to beat

Chemo-immuno in mesothelioma - update

Difícil de superar

10 years follow up - immunotherapy for BRAF-mutated melanoma

Stimulating new combination of two antibody-cytokine fusions

Is the triplet ready for phase 3?

Is adjuvant treatment still standard in macroscopic, resectable stage III melanoma?

Personalized mRNA-vaccination: Practice changer of the future?

Is the induction treatment the new strategy for selected patient group?

Emerging rescue therapies for PD1 refractory melanoma

Triple checkpoint blockade - a new approach?

Impactful studies from ASCO 24 II: Combi-AD

Impactful studies from ASCO 24 I: NADINA

Intralesional therapy with Daromun

Promising activity of brenetafusp in PD-L1 refractory melanoma

Longterm survival after adjuvant targeted therapy

Vaccine in combination with nivolumab for PDL1 resistance

Neoadjuvant intratumoral therapy with Daromun in metastatic melanoma

Lentigo maligna therapy

Progress in neoadjuvant therapy with IO

Adjuvant therapy with dabrafenib and trametinib - final results after 4 years

3-year update on mRNA vaccines in melanoma

mRNA vaccine plus pembrolizumab in adjuvant therapy

A new triplet for metastatic melanoma

Identifying patients with longterm benefits during tebentafusp in mUM

New oncolytic immunotherapy (RP1) after PD-1 failure

Survival data for TT with dabrafenib and trametinib

Promising Results: Triple combination therapy in advanced melanoma

TIL therapy for metastatic melanoma

Consolidation of the use of IO in clinically detectable stage III melanoma

Impactful studies from ASCO 24 III: Cell-therapy

No differences in PFS between the two study arms

A new therapy benchmark for brain-met melanoma patients

Neoadjuvant immunotherapy treatment for melanoma

No hubo diferencias en la PFS entre los dos brazos del estudio

Prometedora actividad de brenetafusp en melanoma refractario a PD-L1

Consolidación del uso de IO en melanoma en estadio III clínicamente detectable

Risultati promettenti: Tripla terapia di combinazione nel melanoma avanzato

Encouraging developmental IO-options

New therapeutic approaches: Get over PD1 resistances?

New perspectives in HPV+ r/m HNSCC

New MOA in r/m HNSCC

New insights in localized HNSCC

De-escalation in ovarian cancer?

New idea: anti-digest for EC?

Clear cell carcinomas benefit from IO therapy